Am Fam Physician. 2025;112(4):369-370
Author disclosure: No relevant financial relationships.
DETAILS FOR THIS REVIEW
Study Population: 48,148 adults with type 2 diabetes and chronic kidney disease (CKD) from 42 trials; patients had CKD stages 1 to 5 diagnosed by Kidney Disease: Improving Global Outcomes guidelines plus at least 3 months of one of the following: moderate to severe albuminuria regardless of estimated glomerular filtration rate (eGFR), eGFR less than 90 mL/min/1.73 m2 with structural abnormalities of the kidney or urinary sediment abnormalities, or eGFR less than 60 mL/min/1.73 m2
Efficacy End Points: Reduction in all-cause death, major adverse cardiovascular events (composite outcomes), and cardiovascular death; improvement in kidney outcomes
Harm End Points: Severe hypoglycemia
| Benefits of using GLP-1 receptor agonists for people with CKD and diabetes |
| 1 in 77 had prevention of death (all-cause mortality) |
| 1 in 48 had prevention of three-point major adverse cardiovascular events (composite outcome including cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke) |
| 1 in 15 had prevention of four-point major adverse cardiovascular events (composite outcome including cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or need for hospitalization or coronary revascularization for unstable angina pectoris or heart failure) |
| Harms of using GLP-1 receptor agonists for people with CKD and diabetes |
| None |
Subscribe
From $180- Immediate, unlimited access to all AFP content
- More than 125 CME credits/year
- AAFP app access
- Print delivery available
Issue Access
$59.95- Immediate, unlimited access to this issue's content
- CME credits
- AAFP app access
- Print delivery available
